Dulaglutide (LY2189265)

Description

Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.

Regulatory Notice – Dulaglutide (Trulicity®): Dulaglutide is an FDA-approved prescription drug marketed as Trulicity® by Eli Lilly. Research-grade dulaglutide powder supplied by BC9 is intended for research use only. It is not a pharmaceutical drug formulation, does not constitute a clinical alternative to Trulicity®, and is not approved for any use. BC9 does not sell pharmaceutical Trulicity®.

Available SKUs – 2 Vial Sizes: Dulaglutide 5mg per vial  · Dulaglutide 10 mg per vial. Identical compound (~63 kDa IgG4-Fc fusion protein), same mechanism, same purity (≥98%). Differentiated by vial mass only to serve different research volume requirements. See the Research Applications section for SKU selection guidance.

Chemical Properties of the Compound

Shared Properties – Both Vial Sizes

SKU Format Details

Overview

Dulaglutide (LY2189265) is a synthetic GLP-1 receptor agonist engineered as a disulfide-bonded homodimeric fusion protein: each monomer consists of a DPP-4-resistant GLP-1(7–37) analogue sequence – carrying Gly8 and Glu22 amino acid substitutions for enzymatic stability – covalently linked via a small peptide linker to a modified human IgG4 Fc heavy chain fragment. The resulting homodimer is approximately 63 kDa, a molecular architecture specifically designed to address the two primary pharmacokinetic liabilities of native GLP-1: a plasma half-life of under two minutes (DPP-4 inactivation and renal clearance) and receptor-level limitations of short-acting agonism. The IgG4-Fc fusion raises molecular weight above the renal filtration threshold and engages FcRn-mediated recycling, extending the plasma half-life to approximately ~5 days (~120 h) in published preclinical and clinical pharmacokinetic models (Glaesner et al. 2010, PMID 20503261). Dulaglutide is FDA-approved (Trulicity®) as a once-weekly GLP-1R agonist for type 2 diabetes management. BC9 supplies research-grade dulaglutide powder strictly for in vitro and preclinical laboratory investigation of GLP-1R pharmacology, Fc-fusion protein engineering, and receptor signalling biology.

Both vial sizes (5mg and 10mg) contain identical compounds at ≥98% purity with the same mechanism and receptor pharmacology. This compound is not FDA-approved for any research or therapeutic use without a prescription. It is not a dietary supplement or consumer product. Availability is restricted to qualified researchers and licensed laboratory institutions. IRB guidance is required for clinical research initiatives. IACUC compliance is required for preclinical animal research.

Working Mechanism of Dulaglutide

GLP-1R → Gs/cAMP/PKA Incretin Signalling: Dulaglutide engages the GLP-1 receptor (GLP-1R), a Class B G-protein-coupled receptor (GPCR) expressed on pancreatic β-cells, intestinal L-cells, hypothalamic neurons, vagal afferent fibres, and multiple peripheral tissues. Receptor engagement proceeds via a two-step binding mechanism: the C-terminal region of the GLP-1 analogue contacts the GLP-1R extracellular N-terminal domain first, followed by insertion of the N-terminal alpha-helix into the receptor transmembrane bundle. This conformational engagement couples Gs-protein → adenylyl cyclase activation → intracellular cAMP elevation → PKA activation. In pancreatic β-cell model systems, PKA phosphorylates KATP channel regulatory subunits and voltage-gated calcium channel proteins, driving glucose-dependent insulin exocytosis. The glucose-dependence of this insulin secretion response is mechanistically significant: membrane depolarisation from elevated glucose is required as a concurrent signal, preventing insulin release under euglycaemic conditions in preclinical models. Published preclinical data (Glaesner et al. 2010, PMID 20503261) document full GLP-1R agonist activity for LY2189265 in vitro in islet cell model systems.

IgG4-Fc Fusion Engineering → Extended Half-Life and Pharmacokinetic Research Utility: Three pharmacokinetically significant outcomes of the IgG4-Fc fusion architecture have been characterized in published data (Glaesner et al. 2010, PMID 20503261; Barrington et al. 2011, PMID 21210908): (1) DPP-4 resistance: the Gly8 substitution blocks the primary DPP-4 cleavage site at Ala8-Glu9, eliminating the dominant GLP-1 inactivation mechanism; (2) renal clearance reduction: the ~63 kDa homodimer exceeds the renal glomerular filtration threshold (~30–50 kDa), dramatically reducing urinary elimination relative to native GLP-1 or small-peptide GLP-1R agonists; (3) FcRn-mediated recycling: the IgG4-Fc domain engages the neonatal Fc receptor (FcRn) in endosomal compartments, enabling transcytotic recycling back to the plasma membrane and extending half-life to ~5 days (~120 hours). These three mechanisms make dulaglutide a pharmacokinetically distinct GLP-1R agonist for receptor occupancy duration and Fc-fusion protein half-life extension research.

5mg vs 10mg – Research Scale Rationale: The 5mg vial provides sufficient material for standard GLP-1R pharmacology assays: cAMP dose-response (4–6 concentration points), competitive radioligand displacement, receptor internalisation kinetics, and single-arm method development studies. The 10mg vial enables more demanding research programmes: full 10+ point concentration-response curves from femtomolar to micromolar concentrations, multi-arm parallel designs across multiple cell lines or co-treatment conditions from a single matched lot, extended longitudinal receptor desensitisation studies, and comparative GLP-1R agonist pharmacology panels requiring matched-batch material across multiple agonist conditions.

Research Findings / Research Applications

Preclinical investigations have examined Dulaglutide (LY2189265) in relation to:

5mg Vial – Standard Assay Research

•       GLP-1R binding kinetics characterisation: Competitive radioligand displacement assays using [125I]-GLP-1 or [125I]-exendin-4 in GLP-1R-transfected HEK-293, MIN6, or INS-1 cell lines. The 5mg vial provides sufficient material for 4–6 concentration-response points per assay run, calibrating dulaglutide’s receptor affinity relative to native GLP-1 and shorter-acting GLP-1R agonists
•       cAMP signalling dose-response: HTRF- or AlphaScreen-based cAMP accumulation assays in GLP-1R-expressing cell lines from picomolar to nanomolar dulaglutide concentrations, characterising Gs-coupling efficiency and EC50 at standard assay volumes
•       GLP-1R internalisation and recycling kinetics: Confocal or ELISA-based surface receptor quantification in GLP-1R-GFP fusion cell lines following dulaglutide stimulation, investigating receptor trafficking and resensitisation kinetics relative to shorter-acting GLP-1R agonists
•       Fc-fusion protein reference standard: Single-lot dulaglutide as a calibrated Fc-GLP-1 reference compound for pharmacokinetic modelling, FcRn binding affinity characterisation by SPR, and GLP-1R assay development method validation

10mg Vial – Extended Pharmacology Research

•       Full concentration-response curve construction: 10+ point sigmoidal dose-response characterisation from femtomolar to micromolar concentrations in cAMP accumulation, β-arrestin recruitment (PathHunter, NanoBRET), and receptor binding assays within a single matched-batch research programme
•       Multi-arm parallel experimental designs: Independent replicate arms across multiple cell lines, co-treatment conditions, or timepoints from a single matched lot – eliminating inter-lot variability as a confounding variable in comparative pharmacology studies
•       Longitudinal GLP-1R desensitisation and resensitisation kinetics: Extended observation window experiments requiring repeated compound addition over 2–4 week periods, investigating long-term receptor adaptation under sustained GLP-1R occupancy from the Fc-fusion architecture’s ~5 days (~120) hour half-life
•       Comparative GLP-1R agonist pharmacology panels: Head-to-head dulaglutide vs semaglutide, liraglutide, or exenatide receptor binding and cAMP signalling studies requiring matched-batch material across multiple agonist concentration series simultaneously

Note: These findings are based on early-stage and preclinical research. Results are not consistent across all models, and data remain limited without validation in human clinical settings.

Risks & Handling Information

•       The use of appropriate personal protective equipment (PPE) is essential in conducting experiments involving dulaglutide. Nitrile gloves, a laboratory coat, and eye protection are required at a minimum.
•       Handling should occur within controlled laboratory environments designed for research activities. Reconstitute under aseptic conditions with bacteriostatic water. Avoid aerosol generation during lyophilized powder handling.
•       Do not inhale, ingest, or make direct skin contact with the compound. Dulaglutide is a physiologically active GLP-1R agonist; unintended biological exposure may activate GLP-1R-mediated insulin secretion, appetite suppression, and gastrointestinal motility pathways in biological systems.
•       Risk Tier: CRITICAL/HIGHEST – Dulaglutide is an FDA-approved GLP-1R agonist prescription drug (Trulicity®). Research-grade powder is not a pharmaceutical formulation. No human safety data has been established for this research reagent. No chronic toxicity data exists for research-grade dulaglutide powder at either vial size. The 10mg vial carries elevated handling caution requirements relative to the 5mg vial due to higher per-vial peptide mass. Any non-research use or distribution may violate applicable federal regulations. Purchaser assumes all liability for lawful use.
•       Improper storage conditions, including exposure to heat, light, or moisture, may result in protein denaturation, aggregation, and compromised research sample integrity. Store lyophilized vials at −20°C in sealed, light-protected containers. Reconstituted solution: do not re-freeze; use within the manufacturer-specified stability window.

FAQs

What is the difference between the 5mg and 10mg vials?

Both contain identical dulaglutide at ≥98% purity with the same GLP-1R mechanism. The 5mg vial is calibrated for standard GLP-1R pharmacology assays at typical laboratory assay volumes (cAMP dose-response, radioligand binding, receptor internalisation, method development). The 10mg vial enables more demanding research: full 10+ point concentration-response characterisation, multi-arm parallel experimental designs across multiple cell lines or timepoints from a single matched lot, extended longitudinal receptor desensitisation studies, and comparative GLP-1R agonist panels requiring higher total reagent volume.

Is research-grade dulaglutide the same as Trulicity®?

Dulaglutide is the active pharmaceutical ingredient in Trulicity®. The amino acid sequence and Fc-fusion architecture are the same. However, this research vial is a lyophilized research reagent – not a pharmaceutical-grade drug product with approved excipients, preservatives, or sterile delivery devices. BC9 does not sell pharmaceutical Trulicity®. These vials are for in vitro and preclinical laboratory research only.

Why does DPP-4 resistance matter for GLP-1R cell-based assay design?

Native GLP-1 has a plasma half-life of under two minutes, largely due to DPP-4 cleavage at the Ala8-Glu9 bond. In serum-containing cell culture media, DPP-4 activity progressively inactivates native GLP-1, complicating accurate EC50 determination and receptor occupancy modelling. Dulaglutide’s Gly8 substitution blocks this cleavage site, providing markedly greater stability in serum-containing assay media. This makes dulaglutide a more stable GLP-1R agonist reference compound than native GLP-1 for assays conducted in serum-containing conditions.

What GLP-1R assay systems are appropriate for dulaglutide research?

Published GLP-1R pharmacology literature has used GLP-1R-transfected HEK-293 cells, native MIN6 murine β-cells, INS-1 rat insulinoma cells, and βTC-6 cells. cAMP accumulation (HTRF or AlphaScreen), radioligand displacement ([125I]-GLP-1), β-arrestin recruitment (PathHunter or NanoBRET), and receptor internalisation (confocal/ELISA) are the documented model systems for GLP-1R agonist characterisation in the published literature.

What storage conditions are required for both vials?

Store both 5mg and 10mg lyophilized vials at −20°C in sealed, light-protected containers. Reconstitute with bacteriostatic water under aseptic conditions immediately before use. Do not refreeze reconstituted solution. Stable ≥24 months, lyophilized under recommended conditions.

What is the documented half-life and its relevance to in vitro research?

Published clinical pharmacokinetic data (Barrington et al. 2011, PMID 21210908) document a dulaglutide half-life of approximately ~5 days (~120) hours in human subjects. In cell-based assay systems without albumin, the plasma half-life does not directly apply. However, the DPP-4 resistance from Gly8 does apply in serum-containing media – making dulaglutide more stable than native GLP-1 in these conditions. Researchers comparing dulaglutide to native GLP-1 in serum-containing assay media should account for this differential stability as a variable in receptor activation kinetics experiments.

References

•       Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metabolism Research and Reviews. 2010;26(4):287–296. https://pubmed.ncbi.nlm.nih.gov/20503261/
•       Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2011;13(5):426–433. https://pubmed.ncbi.nlm.nih.gov/21210908/

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.